Navigation Links
Lipitor Lawsuit News: As Lipitor Diabetes Lawsuits Move Forward, Bernstein Liebhard LLP Comments on JAMA Editorial Expressing Concern about the "Statinization" of U.S.
Date:12/9/2013

NEW YORK, Dec. 9, 2013 /PRNewswire/ -- As Lipitor lawsuits (http://www.thelipitorlawsuit.com/ ) alleging use of the statin caused patients to develop Type 2 diabetes continue to move forward in U.S. courts, Bernstein Liebhard LLP notes that the Journal of the American Medical Association (JAMA) has published a new editorial that expresses concerns about the possible "statinazation" of the U.S. Its December 2nd publication follows the issuance of new guidelines last month by the American Heart Association and the American College of Cardiology that could increase the use of Lipitor and other statins by millions of patients.

(Logo: http://photos.prnewswire.com/prnh/20120202/MM47134LOGO)

Dr. John P. A. Ioannidis, director of the Stanford Prevention Research Center at Stanford University School of Medicine and author of the JAMA editorial, writes that the new guidelines could result in 40 million more Americans between the ages of 40 and 79 who do not have cardiovascular disease being prescribed statins. Among other things, Dr. Ioannidis points to the drugs' possible side effects, including diabetes and myopathy, and warns that the statinazation of America could "be one of the greatest achievements or one of the worst disasters of medical history."

"In light of the growing number of Lipitor diabetes lawsuits that have been filed in courts around the country, the concerns raised by Dr. Ioannidis merit further investigation. Patients considering statins, especially those who do not suffer from heart disease, should be fully apprised of their possible risks," says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to alleged victims of Lipitor and diabetes.

Lipitor Diabetes Lawsuits

In February 2012, the U.S. Food & Drug Administration (FDA) ordered Pfizer, Inc. to add new warnings to the Lipitor label regarding an increased risk of new-onset diabetes in patients who took the cholesterol-lowering statin. The FDA acted after research reported in JAMA: Internal Medicine the preceding month revealed that post-menopausal women treated with Lipitor may be at an increased risk for developing the disease.

A study published just this past May in the British Medical Journal added to growing Lipitor diabetes concerns, after it reported that patients taking Lipitor had a 22 percent higher risk of new-onset diabetes.

Since the FDA issued its warning in 2012, scores of Lipitor lawsuits have been filed in courts around the country by people who allege an association between Lipitor and diabetes. According to court documents, plaintiffs in Lipitor diabetes lawsuits have filed a petition with the U.S. Judicial Panel on Multidistrict Litigation seeking the consolidation of all federally-filed claims in a multidistrict litigation, and transfer of the cases to a single judge in one federal jurisdiction. However, Pfizer is opposed to the creation of a multidistrict litigation for federal Lipitor lawsuits. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502 (JPML))

Alleged victims of Lipitor diabetes may be entitled to compensation for medical bills, lost wages, pain and suffering and more. Find out more about the potential association between Lipitor and diabetes by visiting Bernstein Liebhard LLP's website. For a free, no obligation review of a potential Lipitor lawsuit, please call (888) 340-4807.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(888) 340-4807

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (888) 340-4807. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.thelipitorlawsuit.com/   
https://plus.google.com/115936073311125306742?rel=author

 


'/>"/>
SOURCE Bernstein Liebhard LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Women Injured by Bestselling Diabetes Drug Lipitor Take on Pfizer in St. Louis Circuit Court
2. New Report Examines Efforts to Reduce the Impact of Generic Competition for Popular Drug Lipitor
3. Promotional Trends Report from Encuity Research Shows Maneuvering to Fill Lipitor Vacuum
4. Mylan Launches Generic Version of Lipitor®
5. Mylan Launches Generic Lipitor® in Five European Countries
6. As Da Vinci Robot Lawsuits Mount, Bernstein Liebhard LLP Comments on Latest Da Vinci Robot Instrument Recall
7. Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Says New Study Adds to Debate Surrounding Robotic Surgery
8. Johnson & Johnson Settlement Resolves Metal Hip Lawsuits But Weak Oversight Of Medical Device Industry Leaves Hundreds of Thousands of Patients Vulnerable
9. Unilife Issues Letter to Stockholders Regarding Securities Class Action Lawsuit
10. GenVec Announces Dismissal Of Class Action Lawsuit
11. Jury Returns Verdict in RTI vs. BD Lawsuit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... SAN FRANCISCO , May 23, 2016 ... expected to reach USD 5.0 billion by 2022, according ... The increasing generation of medical waste coupled with the ... healthcare industry is expected to drive the demand for ... with these devices as compared to that of the ...
(Date:5/20/2016)... 2016 The Biotech arena remains ... the industry is not far from recovering. There are ... the following four equities: Anacor Pharmaceuticals Inc. (NASDAQ: ... ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ), ... Sign up for your free trading alerts on these ...
(Date:5/19/2016)... , May 19, 2016  According to the ... the world lacks basic diagnostic imaging. Whereas mammography ... the United States , many places ... technology. In fact, the WHO reports that those ... avoidable or treatable death, simply due to the ...
Breaking Medicine Technology:
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... ... expansion of its services to provide one resource, from start to finish, for ... preparation, Life Safety Statement of Condition surveys requested by the Joint Commission, and ...
(Date:5/24/2016)... ... 24, 2016 , ... i2i, a national leader in population ... “Transforming Outcomes” User Conference in Las Vegas on May 19-20, 2016. The ... the market standard for meaningful population health management. The company recently closed ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... is pleased to welcome new Partner Firm Austin & Co., Inc. Headquartered ... to insurance, employee benefits, HR consulting, benefits technology, and beyond. As an ...
(Date:5/24/2016)... ... May 24, 2016 , ... Educational opportunities, and therefore ... more advantaged communities providing richer opportunities. Recognizing the key role of housing in ... policies; (b) school choice policies; (c) school desegregation policies; (d) wealth-focused policies; and ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... How to ... · Raleigh, NC, http://www.fdanews.com/humanerrordrugdevice , Human error is known to be the ... that human error will ever be totally eliminated, many human performance problems can be ...
Breaking Medicine News(10 mins):